C-peptide

Sana Biotechnology reports positive clinical results for Type 1 Diabetes treatment using HIP technology, enabling islet cell transplantation without immunosuppression. Fast Track designation for SC291 in lupus aims to expedite development. Sana focuses on type 1 diabetes and B-cell mediated diseases, with clinical data expected by 2025. Financial updates show losses, but strategic shifts and investor presentations aim for growth.

Sana Biotechnology's first-in-human study shows HIP-engineered islet cells transplanted into a type 1 diabetes patient survived, functioned, and evaded immune rejection without immunosuppression. C-peptide levels indicated insulin production, and MRI confirmed graft survival. The study suggests potential for scalable, curative treatments for type 1 diabetes.

Sana Biotechnology's first-in-human study shows HIP-engineered islet cells transplanted into a type 1 diabetes patient evade immune rejection and produce insulin without immunosuppression. C-peptide levels indicate insulin production, and MRI confirms graft survival. The study, conducted with Uppsala University Hospital, marks a significant step towards a scalable, curative treatment for type 1 diabetes.

Sana Biotechnology's first-in-human study shows HIP-engineered islet cells transplanted without immunosuppression in a type 1 diabetes patient survived, functioned, and evaded immune detection, evidenced by C-peptide levels and MRI. This breakthrough suggests a potential scalable, curative treatment for type 1 diabetes without immunosuppression.

Sana Biotechnology's first-in-human study shows HIP-engineered islet cells transplanted into a type 1 diabetes patient evade immune rejection and produce insulin without immunosuppression. Results include detectable C-peptide levels, indicating insulin production, and MRI evidence of graft survival. The study aims for a scalable, curative treatment for type 1 diabetes.

Diamyd Medical announced a positive Type C meeting with the FDA, aligning on key components for an accelerated approval pathway for Diamyd®, aiming to make it available to Type 1 Diabetes patients earlier. The early readout for the Phase 3 DIAGNODE-3 trial is planned for March 2026, analyzing efficacy data based on C-peptide levels.

Diamyd Medical is advancing Diamyd®, a therapy for Type 1 Diabetes, through FDA Fast Track designation, aiming for accelerated approval based on C-peptide levels. The DIAGNODE-3 trial, targeting HLA DR3-DQ2 genotype patients, expects interim results by March 2026, with full recruitment by end of 2025.